Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

7.7%

14 terminated/withdrawn out of 182 trials

Success Rate

91.1%

+4.6% vs industry average

Late-Stage Pipeline

23%

41 trials in Phase 3/4

Results Transparency

56%

80 of 144 completed trials have results

Key Signals

11 recruiting80 with results6 terminated8 withdrawn

Enrollment Performance

Analytics

N/A
44(28.6%)
Phase 1
42(27.3%)
Phase 2
27(17.5%)
Phase 4
22(14.3%)
Phase 3
19(12.3%)
154Total
N/A(44)
Phase 1(42)
Phase 2(27)
Phase 4(22)
+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (182)

Showing 20 of 182 trials
NCT06077656Phase 2Completed

Dose-Ranging Study to Evaluate a 25-Valent Pneumococcal Conjugate Vaccine

Role: collaborator

NCT07439185Not ApplicableNot Yet Recruiting

Impact of a Cricket and Black Soldier Fly Larvae-Fortified Cracker on the Gut Microbiome and Iron Status in Malagasy Schoolchildren

Role: collaborator

NCT06390943Not ApplicableCompleted

Low Birthweight and Preterm Infant Feeding Trial and Supportive Care Package: Implementation Research

Role: collaborator

NCT06765863Not ApplicableRecruiting

LIFT-UP: Randomized Controlled Trial of Fortification of Human Milk

Role: collaborator

NCT05879224Not ApplicableCompleted

Short Course Primaquine for the Radical Cure of P. Vivax Malaria - Indonesia

Role: collaborator

NCT05644184Phase 2Recruiting

Study of a Novel Type 1 Oral Poliomyelitis Vaccine in Bangladesh

Role: lead

NCT06895486Phase 2Recruiting

Study of Co-administered (Types 1 & 2) Novel Oral Poliomyelitis Vaccines Evaluation

Role: lead

NCT05874271Not ApplicableCompleted

Short Course Primaquine for the Radical Cure of P. Vivax - Papua New Guinea

Role: collaborator

NCT06611371Phase 1Active Not Recruiting

Phase I/II Study to a Assess the GBS-06 Vaccine Manufactured by Inventprise, Inc., in Healthy, Non-Pregnant, Adult Women of Childbearing Age.

Role: collaborator

NCT05690841Phase 3Recruiting

FocaL Mass Drug Administration for Vivax Malaria Elimination

Role: collaborator

NCT06129916Not Yet Recruiting

Assessing the Acceptability, Feasibility, Effectiveness and Cost-effectiveness of LADB

Role: lead

NCT06395129Recruiting

Low Dead-space Injecting Equipment Distribution Program for People Who Inject Drugs in Low- and Middle-income Countries

Role: collaborator

NCT06879327Phase 2Recruiting

Infant Malaria Vaccine Schedule Optimization

Role: lead

NCT05621876Completed

Evaluation of an IgG Deficiency Rapid Screening Test: A Performance Study With Primary Immunodeficiency (PID) Patients in Tunisia

Role: lead

NCT05758506Completed

Developing a Screening Tool for Primary Immunodeficiency Disease (PID) in Pakistan

Role: lead

NCT06137664Phase 1Recruiting

Study of Trivalent and Bivalent (Types 1 & 2) Novel Oral Poliomyelitis Vaccines

Role: lead

NCT03295318Phase 2Completed

Clinical Study of Meningococcal ACYWX Conjugate Vaccine, in 12-16 Month Olds

Role: collaborator

NCT04658914Phase 2Completed

Human Challenge With Live-attenuated Rotavirus to Assess Next-generation Rotavirus Vaccines in Africa

Role: collaborator

NCT06516042Phase 3Active Not Recruiting

Targeted Antimalarial Drug Administration for Seasonal Migrant Populations in Amhara Region, Ethiopia

Role: lead

NCT05870150Not ApplicableActive Not Recruiting

Challenge Non-Typhoidal Salmonella (CHANTS) Study

Role: collaborator